endocan corp - ENDO

ENDO

Close Chg Chg %
0.00 0.00 0.00%

Closed Market

0.00

0.00 (0.00%)

Volume: 29.00K

Last Updated:

Oct 15, 2024, 9:31 AM EDT

Company Overview: endocan corp - ENDO

ENDO Key Data

Open

$0.00

Day Range

0.00 - 0.00

52 Week Range

0.00 - 0.00

Market Cap

$0.00

Shares Outstanding

67.89M

Public Float

32.89M

Beta

31.19

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.11

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.36K

 

ENDO Performance

No Data Available

ENDO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About endocan corp - ENDO

Endocan Corp. engages in the development of hemp-based products. The company was founded on February 5, 1969 and is headquartered in Colorado Nashville, TN.

ENDO At a Glance

Endocan Corp.
500 Madison Street
Nashville, Tennessee 37208
Phone 1-910-515-2917 Revenue 0.00
Industry Telecommunications Equipment Net Income -3,311,384.00
Sector Electronic Technology Employees N/A
Fiscal Year-end 12 / 2013
View SEC Filings

ENDO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -5.941
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.222

ENDO Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

ENDO Liquidity

Current Ratio 0.00
Quick Ratio 0.00
Cash Ratio 0.00

ENDO Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -1,844,782.173
Return on Equity N/A
Return on Total Capital 640.808
Return on Invested Capital N/A

ENDO Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -190.161
Total Debt to Total Assets 273,721.448
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Endocan Corp - ENDO

Collapse All in section
All values USD millions. 2009 2010 2011 2012 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
- - 532.45K 76.69K
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - 532.45K 76.69K
-
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
- - -85.60% -100.00%
-
Gross Income
- - (532.45K) (76.69K)
-
Gross Income Growth
- - +85.60% +100.00%
-
Gross Profit Margin
- - - -
-
2009 2010 2011 2012 5-year trend
SG&A Expense
40.85K 127.42K 111.24K 743.43K
Research & Development
- - - -
-
Other SG&A
40.85K 127.42K 111.24K 743.43K
SGA Growth
+58.14% +211.90% -12.69% +568.30%
Other Operating Expense
- - - -
-
Unusual Expense
- (464.98K) 1.65M 600.00K
EBIT after Unusual Expense
(108.33K) (204.11K) (1.76M) (1.34M)
Non Operating Income/Expense
- - - 546
-
Non-Operating Interest Income
- - - 546
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
211.50K 5.10M 222.52K 1.97M
Interest Expense Growth
-70.86% +2,311.54% -95.64% +784.39%
Gross Interest Expense
211.50K 5.10M 222.52K 1.97M
Interest Capitalized
- - - -
-
Pretax Income
(319.82K) (5.30M) (1.98M) (3.31M)
Pretax Income Growth
+82.92% -1,558.42% +62.66% -67.18%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(319.82K) (5.30M) (1.98M) (3.31M)
Minority Interest Expense
- - - -
-
Net Income
(319.82K) (5.30M) (1.98M) (3.31M)
Net Income Growth
+82.92% -1,558.42% +62.66% -67.18%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(319.82K) (5.30M) (1.98M) (3.31M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(319.82K) (5.30M) (1.98M) (3.31M)
EPS (Basic)
-0.0666 -0.83 -0.11 -0.1
EPS (Basic) Growth
+95.24% -1,146.25% +86.75% +9.09%
Basic Shares Outstanding
5.31M 6.40M 17.54M 32.71M
EPS (Diluted)
-0.0666 -0.83 -0.11 -0.1
EPS (Diluted) Growth
+95.24% -1,146.25% +86.75% +9.09%
Diluted Shares Outstanding
5.31M 6.40M 17.54M 32.71M
EBITDA
(40.86K) (127.42K) (111.24K) (743.43K)
EBITDA Growth
-103.77% -211.85% +12.70% -568.31%
EBITDA Margin
- - - -
-

Endocan Corp in the News